GUJARAT KIDNEY N SUP SP L GKSL NSEPHARMA
Company Overview
Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.
Why Investors Should Care
Net profit has compounded at 32.7% per year over the last five years.
Maintains a net profit margin of 18.9%.
Carries low leverage with a debt-to-equity ratio of 0.12.
Recent Developments
- Mar 2026 Revenue of ₹82.01 Cr (+103.8% YoY); net profit ₹15.50 Cr.
- Trailing 12 Months Year-on-year growth — revenue +103.8%, earnings +64.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.5%, profit CAGR 32.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.49% |
| 1 Year: | 103.80% |
Compounded Profit Growth
| 5 Years: | 32.67% |
| 1 Year: | 64.63% |
Stock Price Performance
| 1 Year: | +27.31% |
| 6 Months: | +30.26% |
| 3 Months: | +18.77% |
| 1 Month: | +1.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)58.12 · Neutral
P/E of 53.45 is above the sector median of 39.97 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 32.7% over 5 years.
CONS
- Trading at a high P/E of 53.5.
- Revenue declined at -1.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GKSL GUJARAT KIDNEY N SUP SP L NSEPHARMA | 133.09 | 53.45 | ₹1,049.32 Cr | 0.00% | 8.57% | 6.14% | -1.49% | 32.67% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.41 Cr | 11.79 Cr | 9.78 Cr | 31.09 Cr | 12.93 Cr | 23.25 Cr | 30.58 Cr |
| Cost of Revenue | - | 1.03 Cr | 1.57 Cr | 3.25 Cr | - | 3.05 Cr | 3.37 Cr |
| Gross Profit | - | 10.76 Cr | 8.22 Cr | 27.84 Cr | - | 20.19 Cr | 27.21 Cr |
| Operating Expenses | 4.55 Cr | 7.04 Cr | 6.50 Cr | 15.87 Cr | 7.81 Cr | 14.63 Cr | 22.42 Cr |
| Operating Income | 4.12 Cr | 3.71 Cr | 1.72 Cr | 11.97 Cr | 4.22 Cr | 5.56 Cr | 4.79 Cr |
| EBITDA | 4.86 Cr | 4.65 Cr | 2.67 Cr | 13.66 Cr | 5.12 Cr | 6.96 Cr | 7.01 Cr |
| Interest Expense | 16.00 L | 16.65 L | 16.41 L | 50.87 L | 28.00 L | 59.85 L | 81.80 L |
| Pretax Income | 4.00 Cr | 3.60 Cr | 1.60 Cr | 11.52 Cr | 4.03 Cr | 5.03 Cr | 4.69 Cr |
| Tax Provision | 1.05 Cr | 1.07 Cr | 27.13 L | 3.16 Cr | 1.15 Cr | 1.32 Cr | -14.02 L |
| Net Income | 2.96 Cr | 2.50 Cr | 1.28 Cr | 7.80 Cr | 2.88 Cr | 2.94 Cr | 5.04 Cr |
| Diluted EPS | 18.39 | 0.32 | 0.16 | 0.99 | 0.47 | 0.52 | 0.81 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 85.79 Cr | 103.44 Cr | 40.24 Cr | 82.01 Cr |
| Cost of Revenue | 9.79 Cr | 11.16 Cr | 3.96 Cr | 9.12 Cr |
| Gross Profit | 76.01 Cr | 92.28 Cr | 36.28 Cr | 72.90 Cr |
| Operating Expenses | 64.41 Cr | 77.54 Cr | 23.02 Cr | 50.66 Cr |
| Operating Income | 11.60 Cr | 14.74 Cr | 13.26 Cr | 22.24 Cr |
| EBITDA | 17.93 Cr | 22.03 Cr | 16.70 Cr | 27.81 Cr |
| Interest Expense | 2.08 Cr | 2.35 Cr | 64.63 L | 1.88 Cr |
| Pretax Income | 9.84 Cr | 13.57 Cr | 12.77 Cr | 21.23 Cr |
| Tax Provision | 3.48 Cr | 3.60 Cr | 3.27 Cr | 4.42 Cr |
| Net Income | 6.64 Cr | 9.68 Cr | 9.41 Cr | 15.50 Cr |
| Diluted EPS | 0.84 | 1.23 | 1.19 | 2.49 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 63.86 Cr | 65.40 Cr | 91.29 Cr | 297.64 Cr |
| Current Assets | 20.56 Cr | 24.82 Cr | 37.74 Cr | 104.59 Cr |
| Cash & Equivalents | 1.90 Cr | 3.90 Cr | 4.58 Cr | 13.28 Cr |
| Inventory | 68.50 L | 1.04 Cr | 1.45 Cr | 2.06 Cr |
| Receivables | 13.66 Cr | 15.47 Cr | 25.06 Cr | 38.63 Cr |
| Total Liabilities | 41.56 Cr | 42.55 Cr | 51.46 Cr | 42.90 Cr |
| Current Liabilities | 22.54 Cr | 18.32 Cr | 32.77 Cr | 27.82 Cr |
| Long Term Debt | 12.23 Cr | 9.10 Cr | 4.79 Cr | 1.79 Cr |
| Total Debt | 23.20 Cr | 27.34 Cr | 22.77 Cr | 29.11 Cr |
| Total Equity | 21.96 Cr | 22.27 Cr | 38.64 Cr | 252.51 Cr |
| Shares Outstanding | 7.88 Cr | 7.88 Cr | 7.88 Cr | 7.88 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 1,000 | 1.21 Cr | 13.61 Cr | -3.86 Cr |
| Investing Cash Flow | 0 | 22.33 L | -18.14 Cr | -213.85 Cr |
| Financing Cash Flow | 0 | -46.93 L | 6.16 Cr | 228.40 Cr |
| Capital Expenditure | - | - | -18.25 Cr | -153.42 Cr |
| Free Cash Flow | 1,000 | 1.21 Cr | -4.64 Cr | -157.28 Cr |
| Net Change in Cash | 1,000 | 96.68 L | 1.63 Cr | 10.69 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 88.6% | 89.2% | 90.2% | 88.9% |
| Operating Margin % | 13.5% | 14.3% | 32.9% | 27.1% |
| Net Margin % | 7.7% | 9.4% | 23.4% | 18.9% |
| ROE % | 30.2% | 43.5% | 24.4% | 6.1% |
| ROCE % | 28.1% | 31.3% | 22.7% | 8.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GKSL
GKSL Stock Price and Chart — NSE:GKSL - TradingView
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9uT3h5dkZadUc1LW5Qd25LZmxKd3B6YkdhQlQtOHlVa3B6czVUMjhkS2drWjhLWV9UNUg4cFh4SWt2UmZLOUh5ZFdrTkdDdDc4aTNzUV9rRzk?oc=5" target="_blank">GKSL Stock Price and Chart — NSE:GKSL</a> &…
Concerns Surrounding Gujarat Kidney And Super Speciality's (NSE:GKSL) Performance - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNWUp3b0V1aXdJTDhtRUo3V1pPRFRMRkNnQ1daMXBVVEV6Z3lJWkNpUm5tc1dDSFNvUW5XUDVZMmN1cEVxTmhxVEdkdnY4c0h2SVF5akNxbXpMVHk4ZHNRSjRoR2R2TXV0anNYbHBYSXB6TFJ3ZG0xSFRERDExV1FvbTVSSkxUaWtDNHZpYz…
Gujarat Kidney listing: Year’s last IPO falls 8% on debut day - Fortune India
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMFdTaE1lbDZpWnFIWkZrTm1hRzFRNl9wdUFoalZXay1qOEw5amZJNXpxcktvQlROeWgzc0dGUi1uUmE5SVJ2OGphMHBoVGhRS1lQdDQ5cDRNOWx6Y1hFMDNtbklfWHJHc2cySzZEN181OEIyVmdzd0FhQnMwWXdENVR4VWJ3VS1NOWxZN2…
Gujarat Kidney and Super Speciality IPO allotment finalised: Check status online on MUFG Intime India, NSE, BSE; listing date, time here - Upstox
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxOb1VjWmxmZ0Fsd2IxWGtlbnUzSDRzTmpkU3VHSFE5TFVxNi1VQUZtVDdSaVpSVjhQSHdmMlBwczJYNzF3eUNZeWwzX2piZkRCOFhBNHEtYURWUUxiRWxSVk5nc0w2NFZhbmd3Q293QUJ5alA4Rnd1YVRUckVfM01penVNaEc3WGJObkQxRm…
Gujarat Kidney and Super Speciality Ltd. Share Price Live Today - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQenFmRkk1ckhwVUR6eGxNMHVDdkJNeVZKek1WUXJGMmx3Xzh2Vy1kLVVRUWYtRTFScUd6aEx4UkhKQ0xKMDAwVE1qTk5CMEpuMzc1Y2V6U1U1aFIzcjRQWE5aVlAtbjluOEJjR1ZMdDJGc1BRNzhHN0JGOVg5YU9DQUltczl2bllDNDRTZ3…
Gujarat Kidney and Super Speciality to Deploy 100 AI-Powered Haemodialysis Machines Across Gujarat Network - scanx.trade
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxOU0UyV0ZNN2dzN2NhVkxENGhpR3BySXN4aEdURWNsNGxRZ1JtR1A3bmRVU2Naa1pVOV94ZkxQdUpiT2pEWGY3Q2gzYnpFN3k2Um9jUDBDUDZYN05uV295RXVhVjY1enZSWm0xNTRkRXBIZ091V0ZfUXJwN2VzOW9HWE1fSnVrYmRVdzd2Rj…
GKSL — Frequently Asked Questions
What is the current share price of GUJARAT KIDNEY N SUP SP L (GKSL)?
As of 2026-07-15 09:52 IST, GUJARAT KIDNEY N SUP SP L (GKSL) trades at ₹133.09 on NSE. Its 52-week range is ₹99.36 to ₹143.33.
What is the market capitalisation of GKSL?
GUJARAT KIDNEY N SUP SP L (GKSL) has a market capitalisation of ₹1,049.32 Cr on NSE.
What is the P/E ratio of GKSL?
GKSL trades at a trailing price-to-earnings (P/E) ratio of 53.45. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.30.
What is the return on equity (ROE) of GKSL?
GKSL has a return on equity (ROE) of 6.14%. Its return on capital employed (ROCE) is 8.57%.
Is GKSL a good stock to buy?
This page provides a data-driven analysis of GUJARAT KIDNEY N SUP SP L (GKSL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.